The lowering of the price target from $180 to $160 by Barclays suggests a less optimistic outlook on Neurocrine Biosciences' stock performance, which could lead to a short-term negative impact on the stock price. However, the maintained Overweight rating indicates continued confidence in the company's long-term potential.